JNCI Journal of the National Cancer Institute · 2008 · 197 citations · 33 references
MedicineOncologyPharmacologyCancer EpidemiologyCancer PreventionEpidemiologic MethodsCardiovascular DiseasePharmacoepidemiologyCancer Incidence EpidemiologyHazard Ratio ModelingHmg-coa Reductase InhibitorsRandomized Clinical Trials
BACKGROUND: Meta-analyses of trials of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors or statins for cardiovascular disease prevention have failed to show any statistically significant benefit of statins for cancer prevention. However, these trials included relatively young participants, who develop few cancers, and their follow-up periods may have been too short to detect an association between statin use and cancer incidence. We investigated this association in a population of veterans. METHODS: We identified patients using antihypertensive medications but no cholesterol-lowering medications (n = 25,594) and patients using statins (n = 37,248) who were enrolled in the Veterans Affairs New England Healthcare System between January 1, 1997, and December 31, 2005. Age- and multivariable-adjusted Cox proportional hazards models were used to calculate the hazard ratio (HR) and its 95% confidence interval (CI) for cancer incidence, excluding nonmelanoma skin cancer, among patients taking statins compared with patients taking antihypertensive medications and among patients grouped by statin dose (as equivalent simvastatin dose). All statistical tests were two-sided. RESULTS: The absolute incidence of total cancers was 9.4% among statin users and 13.2% among nonusers (difference = 3.8%, 95% CI = 3.3% to 4.3%, P(difference) < .001). Statin users had a statistically significant lower risk for total cancer than nonusers after adjustment for age (HR = 0.76, 95% CI = 0.73 to 0.80) and multiple potential confounders (HR = 0.74, 95% CI = 0.70 to 0.78). After multivariable adjustment, a statistically significantly decreased risk of all cancers was also associated with increasing statin use (P(trend) < .001). CONCLUSIONS: Patients using statins may be at lower risk for developing cancer. Additional observational studies and randomized trials of statins for cancer prevention are warranted.
33
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text
Statins and the Risk of Colorectal Cancer
Jenny N. Poynter, Stephen B. Gruber, Peter Higgins et al. · New England Journal of Medicine · 2005 · 826 citations
Medicine, Oncology, Pharmacology +12
The Risk of Cancer in Users of Statins
Matthijs R. Graaf, Annette B. Beiderbeck, Toine C. G. Egberts et al. · Journal of Clinical Oncology · 2004 · 526 citations · Full text
Medicine, Oncology, Pharmacology +10